ClinicalTrials.gg
Drug

Ponatinib clinical trials

Also written AP24534 and Iclusig.

studies test it
52
open now
9
in phase 3
5
first study started
2008

How each study uses ponatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ponatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
14 Dec 2012 · ICLUSIG · NDA 203469 (FDA, Drugs@FDA)
European Union
1 Jul 2013 · Iclusig · EMEA/H/C/002695 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ponatinib
37
Ponatinib Hydrochloride
7
Ponatinib 30 MG
3
Ponatinib 15 MG
2
multitargeted tyrosine kinase inhibitor AP24534
2

Brand

Iclusig
20

Development codes

AP24534
22

Studies by the year they started

52 studies that test it; most in 2013 (7)

Studies that test ponatinib, by start year
YearStudies
20081
20101
20111
20124
20137
20142
20154
20163
20172
20185
20195
20204
20217
20222
20231
20241
20251
20261

Who runs them

Industry 12 · Other 40

M.D. Anderson Cancer Center (9) · Ariad Pharmaceuticals (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Takeda (3) · Versailles Hospital (3) · Dana-Farber Cancer Institute (2) · Centre Leon Berard (1) · Otsuka Beijing Research Institute (1)

Often tested with

Tested in the same studies.

Blinatumomab (5) · Cytarabine (3) · Venetoclax (3) · Dasatinib (3) · Imatinib (2) · Azacitidine (2) · Methotrexate (2) · Decitabine (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test ponatinib, phase 3 first.

Studies

Open first, then newest update. How each study uses ponatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 52

See all 52 studies that test ponatinib →

Given beside what is tested · 7 — ponatinib is usual care or a partner of the new treatment

Codes

What other systems call ponatinib · ClinicalTrials.gg INT005531

  • MeSH (NLM) C545373ponatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 4340891KFSPONATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1364347Confirmed FDA, Wikidata
  • Wikidata Q198728ponatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C95777PonatinibOne source FDA
  • DrugBank DB08901One source Wikidata

Also registered as ponatinib hydrochloride (UNII 96R6PU3D8J · RxNorm 1364953).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.